Acrylic matrix type nicotine transdermal patches: In vitro evaluations and batch-to-batch uniformity

被引:24
作者
Pongjanyakul, T
Prakongpan, S
Priprem, A
机构
[1] Khon Kaen Univ, Fac Pharmaceut Sci, Khon Kaen 40002, Thailand
[2] Mahidol Univ, Fac Pharm, Bangkok 10700, Thailand
关键词
nicotine transdermal patch; adhesive matrix; in vitro release and skin permeation; rate control; batch-to-batch uniformity;
D O I
10.1081/DDC-120024180
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nicotine transdermal patches (NTPs) were fabricated using an acrylic pressure sensitive adhesive emulsion to form a transparent matrix film. An automated thin layer chromatography (TLC) plate scraper was Used to control the thickness of the cast nicotine matrix film. The in vitro release behavior and permeation of nicotine across abdominal human epidermis (HE) from the NTPs was Studied using United States Pharmacopeia (USP) dissolution apparatus 5 (paddle over disk) and modified Franz-diffusion cell, respectively. The release of nicotine from the NTPs showed a good linear correlation with the square root of time (R-2 >0.99). This indicated a matrix diffusion controlled-release mechanism. The surface morphology of the matrix of the NTP was uniform and nonporous before and after release, indicating that the dried adhesive nicotine matrix was a homogeneous single-phase film. Neither the nicotine content in the range 4.70-8.41% w/w nor the film thicknesses of the NTPs affected the apparent diffusion coefficient of nicotine in the acrylic matrix. A good relationship between the amount of nicotine permeated across the HE and the square root of time was also observed with R-2 >0.98. This Study also showed that the NTPs provided a good delivery system with more than 65% of the nicotine delivery being controlled by the device. Moreover, the release of nicotine from six production batches met the criteria of USP 24. This finding presented a good potential of this method for upscaling to industrial manufacturing.
引用
收藏
页码:843 / 853
页数:11
相关论文
共 23 条
[1]  
[Anonymous], 1993, PHARM ACTA HELV, DOI DOI 10.1016/0031-6865(93)90005-Q
[2]  
Baker Richard W., 1987, US Patent, Patent No. [4,839,174, 4839174]
[3]  
Baker RW, 1989, TRANSDERMAL DRUG DEL, P293
[4]   Design of controlled release inert matrices of naltrexone hydrochloride based on percolation concepts [J].
Caraballo, I ;
Melgoza, LM ;
Alvarez-Fuentes, J ;
Soriano, MC ;
Rabasco, AM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 181 (01) :23-30
[5]  
ELARINI SK, 1995, INT J PHARMACEUT, V121, P141
[6]  
Franz TJ, 1992, TREATISE CONTROLLED, P341
[7]   TRANSDERMAL DELIVERY OF METOPROLOL .1. COMPARISON BETWEEN HAIRLESS MOUSE AND HUMAN CADAVER SKIN AND EFFECT OF N-DECYLMETHYL SULFOXIDE [J].
GHOSH, TK ;
HABIB, MJ ;
CHILDS, K ;
ALEXANDER, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 88 (1-3) :391-396
[8]   INVITRO RELEASE AND PERMEATION OF LEVOBUNOLOL FROM VARIOUS TRANSDERMAL FORMULATIONS [J].
GHOSH, TK ;
CHIAO, CS ;
GOKHALE, RD .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 82 (1-2) :39-45
[9]   TRANSDERMAL DELIVERY OF METOPROLOL .2. IN-VITRO SKIN PERMEATION AND BIOAVAILABILITY IN HAIRLESS RATS [J].
GHOSH, TK ;
ADIR, J ;
XIANG, SL ;
ONYILOFUR, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (02) :158-160
[10]   BIOAVAILABILITY AND ABSORPTION KINETICS OF NICOTINE FOLLOWING APPLICATION OF A TRANSDERMAL SYSTEM [J].
GUPTA, SK ;
BENOWITZ, NL ;
JACOB, P ;
ROLF, CN ;
GORSLINE, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (03) :221-227